

4th July 2024

EXPANSION OF ACCESS TO CONTINUOUS GLUCOSE MONITORS FOR PEOPLE WITH CFRD

Cystic Fibrosis Australia (CFA) warmly welcomes the release of the final report of the Inquiry into Diabetes. We are particularly pleased with the positive recommendation to expand access to continuous glucose monitors (CGMs) for all individuals living with cystic fibrosis-related diabetes (CFRD). This recommendation represents a vital step forward in supporting and improving the care of individuals affected by CFRD.

CGMs play a pivotal role in diabetes management, allowing for continuous blood glucose monitoring and providing real-time data to patients and healthcare providers. These devices are particularly valuable for people with CFRD, as they offer crucial insights into glucose fluctuations caused by CF-related factors, such as infections or pulmonary exacerbations.

Currently, only those with CFRD under 21 years of age are eligible for free access to CGMs through the National Diabetes Support Scheme. This exclusion leaves an estimated 500 Australians with CFRD unable to effectively track and manage their diabetic control, adding significant financial burdens to their healthcare management.

Cystic Fibrosis Australia has been actively advocating for this change, and our submission (number 71) was credibly referenced in the Final Report. Our continuous efforts over the years have included working closely with healthcare professionals,

policymakers, and the wider CF community to ensure that the needs of those with CFRD are heard and addressed.

This report and its recommendation signify a substantial advancement in the support and care for the cystic fibrosis community, particularly those affected by CFRD. CFA is committed to ensuring these changes are implemented and call on the Government and all Stakeholders to act swiftly on this recommendation to make CGMs accessible to all individuals with CFRD.

Read the Full Inquiry into Diabetes Report Here

Warm Regards,

Jo Armstrong

CEO

Cystic Fibrosis Australia